Alnylam Pharmaceuticals (ALNY) Net Cash Flow (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.66% |
| Dec 31, 2025 | -54.56% |
| Sep 30, 2025 | 471.61% |
| Jun 30, 2025 | 67.19% |
| Mar 31, 2025 | 133.92% |
| Dec 31, 2024 | -200.31% |
| Sep 30, 2024 | -59.87% |
| Jun 30, 2024 | 340.88% |
| Mar 31, 2024 | 48.01% |
| Dec 31, 2023 | -160.56% |
| Sep 30, 2023 | 2,768.90% |
| Jun 30, 2023 | 92.71% |
| Mar 31, 2023 | 5.82% |
| Dec 31, 2022 | -142.06% |
| Sep 30, 2022 | 885.13% |
| Jun 30, 2022 | 117.74% |
| Mar 31, 2022 | -4.57% |
| Dec 31, 2021 | -177.16% |
| Sep 30, 2021 | -3.68% |
| Jun 30, 2021 | 422.62% |